A New Index to Predict Quality of Anticoagulation Control in Patients On Vitamin K Antagonists: the Dafne Score

References

• Lip GYH , BanerjeeA, BorianiGet al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest, 154(5), 1121–1201 (2018).
   PubMed Web of Science ®Google Scholar
• Huisman MV , RothmanKJ, PaquetteMet al. The changing landscape for stroke prevention in AF: Findings from the GLORIA-AF registry Phase II. J. Am. Coll. Cardiol., 69(7), 777–785 (2017).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, PrietoLet al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Rev. Esp. Cardiol., 68(9), 769–776 (2015).
   PubMed Web of Science ®Google Scholar
• Vinding NE , BondeAN, RørthRet al. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Europace, 21(4), 572–580 (2019).
   PubMed Web of Science ®Google Scholar
• Apostolakis S , SullivanRM, OlshanskyB, LipGYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest, 144(5), 1555–1563 (2013).
   PubMed Web of Science ®Google Scholar
• Zulkifly H , LipGYH, LaneDA. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review. Heart. Rhythm., 15(4), 615–623 (2018).
   PubMed Web of Science ®Google Scholar
• Gallego P , RoldánV, MarinFet al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am. J. Med., 127(11), 1083–1088 (2014).
   PubMed Web of Science ®Google Scholar
• Lobos-Bejarano JM , BarriosV, Polo-GarcíaJet al. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. Curr. Med. Res. Opin., 32(7), 1201–1207 (2016).
   PubMed Web of Science ®Google Scholar
• Escobar C , BarriosV, LobosJM, PrietoL. SAMe-TT2R2 score: useful in all patients with nonvalvular atrial fibrillation?Rev. Esp. Cardiol., 69(8), 798 (2016).
   PubMed Web of Science ®Google Scholar
• Bertomeu-González V , AnguitaM, Moreno-ArribasJet al. Quality of anticoagulation with Vitamin K antagonists. Clin. Cardiol., 38(6), 357–364 (2015).
   PubMed Web of Science ®Google Scholar
• Escobar C , BarriosV, PrietoL. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. Eur. J. Intern. Med., 30, e17–e18 (2016).
   PubMed Web of Science ®Google Scholar
• Escobar C , BarriosV, PrietoL, LobosJM, PoloJ, VargasD. Perception of patients regarding burdens and benefits of vitamin K antagonists among patients with nonvalvular atrial fibrillation. Cardiovasc. Hematol. Agents. Med. Chem., 16(2), 106–103 (2018).
   PubMedGoogle Scholar
• Barrios V , EscobarC, PrietoL, LobosJM, PoloJ, VargasD. Control of anticoagulation with warfarin or acenocoumarol in spain. do they differ?Rev. Esp. Cardiol., 68(12), 1181–1182 (2015).
   PubMed Web of Science ®Google Scholar
• Williams BA , EvansMA, HonushefskyAM, BergerPB. Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation. J. Am. Heart Assoc., 6(10), e006669 (2017).
   PubMed Web of Science ®Google Scholar
• Numao Y , SuzukiS, AritaTet al. Predictors of international normalized ratio variability in patients with atrial fibrillation under warfarin therapy. Circ. J., 82(1), 39–45 (2017).
   PubMed Web of Science ®Google Scholar
• Martín-Pérez M , GaistD, de AbajoFJ, RodríguezLAG. Population impact of drug interactions with warfarin: a real-world data approach. Thromb. Haemost., 118(3), 461–470 (2018).
   PubMed Web of Science ®Google Scholar
• Martín-Pérez M , GaistD, de AbajoFJ, GarcíaRodríguez LA. Predictors of over-anticoagulation in warfarin users in the UK general population: a nested case-control study in a primary health care database. Thromb. Haemost., 119(1), 66–76 (2019).
   PubMed Web of Science ®Google Scholar
• Roldán V , CancioS, GálvezJet al. The SAMe-TT2R2 score predicts poor anticoagulation control in af patients: a prospective ‘real-world’ inception cohort study. Am. J. Med., 128(11), 1237–1243 (2015).
   PubMed Web of Science ®Google Scholar
• Mwita JC , FrancisJM, OyekunleAA, GaenamongM, GoepamangM, MagafuMGMD. Quality of anticoagulation with warfarin at a tertiary hospital in Botswana. Clin. Appl. Thromb. Hemost., 24(4), 596–601 (2018).
   PubMed Web of Science ®Google Scholar
• Gateman D , TrojnarME, AgarwalG. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can. Fam. Physician, 63(10), e425–e431 (2017).
   PubMed Web of Science ®Google Scholar